|Bid||133.70 x 700|
|Ask||133.80 x 1900|
|Day's Range||133.62 - 134.06|
|52 Week Range||99.60 - 136.83|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.35%|
The iShares NASDAQ Biotechnology ETF (IBB) is an open-end fund with assets under management of $9.85 billion.
Gilead Sciences' (GILD) portfolio includes various drugs for key therapeutic areas including HIV/AIDS, liver diseases, oncology, cardiovascular, inflammation, respiratory, and others.
The biotech sector has been on fire this summer, but the good times aren’t all behind us. Cann writes that using a relative Price-to-earnings-growth ratio, the biotech sector is still almost a full deviation below a sell-signal level. The biotech group relative P/E had generally been contracting from 2015 to the end of May 2017.